Compare AMETEK, Inc. (AME) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Novo Nordisk A/S — how do they compare? AMETEK, Inc. trades at $232.13 (market cap $53.63B), while Novo Nordisk A/S trades at $49.19 (market cap $216.71B). The key difference: Novo Nordisk A/S is far larger — about 4× AMETEK, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.64%). Which is the better fit depends on your goals.
| AME | NVO | |
|---|---|---|
Market Cap | $53.63B | $216.71B |
Sector | Industrials | Health |
52-Week High | $241.94 | $71.70 |
52-Week Low | $176.44 | $35.29 |
Enterprise Value | $55.33B | $235.67B |
Dividend Yield | 0.58% | 3.64% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
